Compounds > salvinorin b

Page last updated: 2024-11-12

salvinorin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

salvinorin B: from the herb, Salvia divinorum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Flora	Rank	Flora Definition	Family	Family Definition
Salvia	genus	A genus in the mint family (LAMIACEAE).[MeSH]	Lamiaceae	The mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]

Cross-References

ID Source	ID
PubMed CID	11440685
CHEMBL ID	424698
CHEBI ID	177592
SCHEMBL ID	3144611
MeSH ID	M0495728

Synonyms (26)

Synonym
92545-30-7
CHEBI:177592
methyl (2s,4ar,6ar,7r,9s,10as,10br)-2-(uran-3-yl)-9-hydroxy-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1h-benzo[]isochromene-7-carboxylate
salvinorin b
NCGC00181787-01
bdbm50189136
CHEMBL424698 ,
(2s,4ar,6ar,7r,9s,10as,10br)-2-(3-furanyl)dodecahydro-9-hydroxy-6a,10b-dimethyl-4,10-dioxo-2h-naphtho[2,1-c]pyran-7-carboxylic acid methyl ester
divinorin b
(-)-salvinorin b
BLTMVAIOAAGYAR-CEFSSPBYSA-N
SCHEMBL3144611
salvinorin b, >=93.0% (hplc)
DTXSID50465988
AKOS027326793
c21h26o7
HB4887
salvinorin b (salb)
methyl (2s,4ar,6ar,7r,9s,10as,10br)-2-(furan-3-yl)-9-hydroxy-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1h-benzo[f]isochromene-7-carboxylate
salvinorin b 100 microg/ml in acetonitrile
Q9333044
XS139260
2h-naphtho(2,1-c)pyran-7-carboxylic acid, 2-(3-furanyl)dodecahydro-9-hydroxy-6a,10b-dimethyl-4,10-dioxo-, methyl ester, (2s,4ar,6ar,7r,9s,10as,10br)-
6HNB6FRT7X ,
methyl (2r,4ar,6ar,7s,9r,10as,10br)-2-(furan-3-yl)-6a,10b-dimethyl-9-oxidanyl-4,10-bis(oxidanylidene)-2,4a,5,6,7,8,9,10a-octahydro-1h-benzo(f)isochromene-7-carboxylate
unii-6hnb6frt7x

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
diterpene lactone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Delta-type opioid receptor	Mus musculus (house mouse)	Ki	1.0000	0.0000	0.5393	9.4000	AID1250603
Mu-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	1.0000	0.0000	0.3845	8.6000	AID1250605
Mu-type opioid receptor	Homo sapiens (human)	Ki	10.0000	0.0000	0.4197	10.0000	AID291854; AID329899; AID747129
Delta-type opioid receptor	Homo sapiens (human)	Ki	10.0000	0.0000	0.5978	9.9300	AID291855; AID329900; AID747128
Kappa-type opioid receptor	Homo sapiens (human)	Ki	1.8118	0.0000	0.3624	10.0000	AID1250604; AID239298; AID270608; AID291856; AID329901; AID747126
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Kappa-type opioid receptor	Homo sapiens (human)	EC50 (µMol)	0.1862	0.0000	0.2244	8.9900	AID1250606; AID1482220; AID240367; AID270609
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (52)

Process	via Protein(s)	Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Mu-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
sensory perception	Mu-type opioid receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Mu-type opioid receptor	Homo sapiens (human)
sensory perception of pain	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
behavioral response to ethanol	Mu-type opioid receptor	Homo sapiens (human)
positive regulation of neurogenesis	Mu-type opioid receptor	Homo sapiens (human)
negative regulation of Wnt protein secretion	Mu-type opioid receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Mu-type opioid receptor	Homo sapiens (human)
calcium ion transmembrane transport	Mu-type opioid receptor	Homo sapiens (human)
cellular response to morphine	Mu-type opioid receptor	Homo sapiens (human)
regulation of cellular response to stress	Mu-type opioid receptor	Homo sapiens (human)
regulation of NMDA receptor activity	Mu-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
immune response	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Delta-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
adult locomotory behavior	Delta-type opioid receptor	Homo sapiens (human)
negative regulation of gene expression	Delta-type opioid receptor	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Delta-type opioid receptor	Homo sapiens (human)
positive regulation of CREB transcription factor activity	Delta-type opioid receptor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Delta-type opioid receptor	Homo sapiens (human)
response to nicotine	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
eating behavior	Delta-type opioid receptor	Homo sapiens (human)
regulation of mitochondrial membrane potential	Delta-type opioid receptor	Homo sapiens (human)
regulation of calcium ion transport	Delta-type opioid receptor	Homo sapiens (human)
cellular response to growth factor stimulus	Delta-type opioid receptor	Homo sapiens (human)
cellular response to hypoxia	Delta-type opioid receptor	Homo sapiens (human)
cellular response to toxic substance	Delta-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
immune response	Kappa-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
chemical synaptic transmission	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception	Kappa-type opioid receptor	Homo sapiens (human)
locomotory behavior	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception of pain	Kappa-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
response to insulin	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of dopamine secretion	Kappa-type opioid receptor	Homo sapiens (human)
negative regulation of luteinizing hormone secretion	Kappa-type opioid receptor	Homo sapiens (human)
response to nicotine	Kappa-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
maternal behavior	Kappa-type opioid receptor	Homo sapiens (human)
eating behavior	Kappa-type opioid receptor	Homo sapiens (human)
response to estrogen	Kappa-type opioid receptor	Homo sapiens (human)
estrous cycle	Kappa-type opioid receptor	Homo sapiens (human)
response to ethanol	Kappa-type opioid receptor	Homo sapiens (human)
regulation of saliva secretion	Kappa-type opioid receptor	Homo sapiens (human)
behavioral response to cocaine	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception of temperature stimulus	Kappa-type opioid receptor	Homo sapiens (human)
defense response to virus	Kappa-type opioid receptor	Homo sapiens (human)
cellular response to lipopolysaccharide	Kappa-type opioid receptor	Homo sapiens (human)
cellular response to glucose stimulus	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of p38MAPK cascade	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Kappa-type opioid receptor	Homo sapiens (human)
response to acrylamide	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of eating behavior	Kappa-type opioid receptor	Homo sapiens (human)
conditioned place preference	Kappa-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Process	via Protein(s)	Taxonomy
G-protein alpha-subunit binding	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor activity	Mu-type opioid receptor	Homo sapiens (human)
beta-endorphin receptor activity	Mu-type opioid receptor	Homo sapiens (human)
voltage-gated calcium channel activity	Mu-type opioid receptor	Homo sapiens (human)
protein binding	Mu-type opioid receptor	Homo sapiens (human)
morphine receptor activity	Mu-type opioid receptor	Homo sapiens (human)
G-protein beta-subunit binding	Mu-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor activity	Delta-type opioid receptor	Homo sapiens (human)
protein binding	Delta-type opioid receptor	Homo sapiens (human)
receptor serine/threonine kinase binding	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled enkephalin receptor activity	Delta-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor activity	Kappa-type opioid receptor	Homo sapiens (human)
protein binding	Kappa-type opioid receptor	Homo sapiens (human)
receptor serine/threonine kinase binding	Kappa-type opioid receptor	Homo sapiens (human)
dynorphin receptor activity	Kappa-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Kappa-type opioid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Process	via Protein(s)	Taxonomy
endosome	Mu-type opioid receptor	Homo sapiens (human)
endoplasmic reticulum	Mu-type opioid receptor	Homo sapiens (human)
Golgi apparatus	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Mu-type opioid receptor	Homo sapiens (human)
axon	Mu-type opioid receptor	Homo sapiens (human)
dendrite	Mu-type opioid receptor	Homo sapiens (human)
perikaryon	Mu-type opioid receptor	Homo sapiens (human)
synapse	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Mu-type opioid receptor	Homo sapiens (human)
neuron projection	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Delta-type opioid receptor	Homo sapiens (human)
synaptic vesicle membrane	Delta-type opioid receptor	Homo sapiens (human)
dendrite membrane	Delta-type opioid receptor	Homo sapiens (human)
presynaptic membrane	Delta-type opioid receptor	Homo sapiens (human)
axon terminus	Delta-type opioid receptor	Homo sapiens (human)
spine apparatus	Delta-type opioid receptor	Homo sapiens (human)
postsynaptic density membrane	Delta-type opioid receptor	Homo sapiens (human)
neuronal dense core vesicle	Delta-type opioid receptor	Homo sapiens (human)
plasma membrane	Delta-type opioid receptor	Homo sapiens (human)
neuron projection	Delta-type opioid receptor	Homo sapiens (human)
nucleoplasm	Kappa-type opioid receptor	Homo sapiens (human)
mitochondrion	Kappa-type opioid receptor	Homo sapiens (human)
cytosol	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Kappa-type opioid receptor	Homo sapiens (human)
membrane	Kappa-type opioid receptor	Homo sapiens (human)
sarcoplasmic reticulum	Kappa-type opioid receptor	Homo sapiens (human)
T-tubule	Kappa-type opioid receptor	Homo sapiens (human)
dendrite	Kappa-type opioid receptor	Homo sapiens (human)
synaptic vesicle membrane	Kappa-type opioid receptor	Homo sapiens (human)
presynaptic membrane	Kappa-type opioid receptor	Homo sapiens (human)
perikaryon	Kappa-type opioid receptor	Homo sapiens (human)
axon terminus	Kappa-type opioid receptor	Homo sapiens (human)
postsynaptic membrane	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Kappa-type opioid receptor	Homo sapiens (human)
neuron projection	Kappa-type opioid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay ID	Title	Year	Journal	Article
AID1250608	Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes at 3 uM	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.
AID329899	Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Herkinorin analogues with differential beta-arrestin-2 interactions.
AID1482220	Agonist activity at human kappa-type opioid receptor expressed in CHO-K1 cells assessed as forskolin-induced cAMP accumulation after 30 mins in presence of forskolin by luminescence-based HitHunter cAMP assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.
AID1250604	Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.
AID270608	Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18).
AID270610	Enhancement of [35S]GTP-gamma-S binding to human KOR expressed in CHO cells relative to U50,488H	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18).
AID1482222	Agonist activity at human delta-type opioid receptor expressed in CHO-K1 cells assessed as forskolin-induced cAMP accumulation up to 10 uM after 30 mins in presence of forskolin by luminescence-based HitHunter cAMP assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.
AID329901	Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Herkinorin analogues with differential beta-arrestin-2 interactions.
AID1250605	Displacement of [3H]diprenorphine from rat mu opioid receptor expressed in CHO cell membranes	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.
AID1250609	Displacement of [3H]diprenorphine from FLAG-tagged mouse delta opioid receptor expressed in CHO cell membranes Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes at 3 uM	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.
AID1250606	Agonist activity at human kappa opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.
AID1250607	Agonist activity at human kappa opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding relative to U50,488H	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.
AID747128	Displacement of [3H]DADLE from delta opioid receptor (unknown origin)	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.
AID243417	Activation of human Opioid receptor kappa 1 expressed in chinese hamster ovary cells to enhance [35S]GTP-gamma-S, binding compared to U50,488H	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2).
AID1482221	Agonist activity at human kappa-type opioid receptor expressed in CHO-K1 cells assessed as forskolin-induced cAMP accumulation up to 10 uM after 30 mins in presence of forskolin by luminescence-based HitHunter cAMP assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.
AID291854	Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15	Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
AID291858	Selectivity for kappa opioid receptor over delta opioid receptor	2007	Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15	Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
AID747126	Displacement of [3H]U69593 from kappa opioid receptor (unknown origin)	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.
AID291857	Selectivity for kappa opioid receptor over mu opioid receptor	2007	Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15	Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
AID329900	Displacement of [125I]IOXY from human recombinant delta opioid receptor expressed in CHO cells	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Herkinorin analogues with differential beta-arrestin-2 interactions.
AID747129	Displacement of [3H]DAMGO from mu opioid receptor (unknown origin)	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.
AID1250610	Displacement of [3H]diprenorphine from rat mu opioid receptor expressed in CHO cell membranes Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes at 3 uM	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.
AID1482223	Agonist activity at human mu-type opioid receptor expressed in CHO-K1 cells assessed as forskolin-induced cAMP accumulation up to 10 uM after 30 mins in presence of forskolin by luminescence-based HitHunter cAMP assay	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.
AID329903	Selectivity for human recombinant kappa opioid receptor over human recombinant delta opioid receptor	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Herkinorin analogues with differential beta-arrestin-2 interactions.
AID329902	Selectivity for human recombinant kappa opioid receptor over human recombinant mu opioid receptor	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Herkinorin analogues with differential beta-arrestin-2 interactions.
AID291855	Displacement of [125I]IOXY from human delta opioid receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15	Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
AID291856	Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells	2007	Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15	Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
AID270609	Enhancement of [35S]GTP-gamma-S binding to human KOR expressed in CHO cells	2006	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17	Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18).
AID240367	Effective concentration for activation of human Opioid receptor kappa 1 expressed in chinese hamster ovary cells to enhance [35S]GTP-gamma-S, binding	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2).
AID239298	Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2).
AID1250603	Displacement of [3H]diprenorphine from FLAG-tagged mouse delta opioid receptor expressed in CHO cell membranes	2015	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20	Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	12 (48.00)	29.6817
2010's	12 (48.00)	24.3611
2020's	1 (4.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	36.52 (24.57)
Research Supply Index	3.26 (2.92)
Research Growth Index	4.54 (4.65)
Search Engine Demand Index	50.49 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (36.52)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	25 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
oxidopamine Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).	3.04	1	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
u 69593 U 69593: selective ligand for opioid K-receptor. U69593 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of phenylacetic acid and the secodary amino group of (5R,7S,8S)-N-methyl-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-amine.	2.03	1	monocarboxylic acid amide; N-alkylpyrrolidine; organic heterobicyclic compound; oxaspiro compound	anti-inflammatory agent; diuretic; kappa-opioid receptor agonist
salvinorin a salvinorin A: from the herb, Salvia divinorum	4.25	17	organic heterotricyclic compound; organooxygen compound	metabolite; oneirogen
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-isomer [no description available]	2.11	1
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	2.13	1	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
etorphine [no description available]	2.11	1	alcohol; morphinane alkaloid	opioid analgesic; opioid receptor agonist; sedative
u-50488 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer: A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21). U50488 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of 3,4-dichlorophenylacetic acid and the secondary amino group of (1R,2R)-N-methyl-2-(pyrrolidin-1-yl)cyclohexanamine	2.72	3	dichlorobenzene; monocarboxylic acid amide; N-alkylpyrrolidine	analgesic; antitussive; calcium channel blocker; diuretic; kappa-opioid receptor agonist
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	2.04	1	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
enkephalin, ala(2)-mephe(4)-gly(5)- [no description available]	2.46	2	peptide
naltrindole naltrindole: delta opioid receptor antagonist	2.08	1	isoquinolines
st 1936 2-(5-chloro-2-methyl-1H-indol-3-yl)-N,N-dimethylethanamine: a 5-HT6 receptor agonist	3.04	1
9-(benzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2h-naphtho(2,1-c)pyran-7-carboxylic acid methyl ester 9-(benzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho(2,1-c)pyran-7-carboxylic acid methyl ester: structure in first source	2.04	1
salvinorin b ethoxymethyl ether salvinorin B ethoxymethyl ether: structure in first source	2.05	1
22-thiocyanatosalvinorin a 22-thiocyanatosalvinorin A: structure in first source	2.08	1
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	3.47	2	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
clozapine n-oxide clozapine N-oxide: structure given in first source	3.47	2	dibenzodiazepine

Condition	Relationship Strength	Studies
Recrudescence [description not available]	2.13	1
Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.	2.13	1
Autosomal Dominant Juvenile Parkinson Disease [description not available]	3.04	1
Dyskinesia, Medication-Induced [description not available]	3.04	1
Complication, Postoperative [description not available]	3.04	1
Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)	3.04	1
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	3.04	1
Parkinsonian Disorders A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.	3.04	1
Allodynia [description not available]	2.15	1
Innate Inflammatory Response [description not available]	2.15	1
Nerve Pain [description not available]	2.15	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.15	1
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	2.15	1

chemdatabank.com